健脾温肾汤化裁治疗缓解期溃疡性结肠炎（脾肾阳虚证）的临床研究

发布时间：2018-10-12 06:39

【摘要】：目的:观察健脾温肾汤在维持治疗缓解期溃疡性结肠炎(脾肾阳虚证)的临床疗效及安全性;比较健脾温肾汤与美沙拉嗪肠溶片在治疗缓解期溃疡性结肠炎过程中的复发率。方法:选取2015年1月至2015年7月就诊于安阳市中医院肝胆脾胃科门诊符合纳入标准、排除标准的受试者68例,随机分为实验组34例与照组34例。实验组给予健脾温肾汤,对照组给予美沙拉嗪肠溶片治疗,疗程为12周。详细记录受试者治疗过程中的症状变化及复发率。疗程结束后受试者来院复查,并将所收集的数据资料统计汇总,建立数据库,用SPSS18.0软件进行统计、分析,记录统计结果。结果:1.综合疗效比较,实验组综合疗效有效率93.76%,对照组综合疗效有效率87.88%,实验组与对照组综合疗效比较,P0.05,具有明显差异。2.中医症候疗效比较,实验组中医症候疗效有效率96.86%,对照组中医症候疗效有效率63.64%,组内比较,实验组治疗前与治疗后各症候比较,P0.05,具有明显差异;对照组治疗前与治疗后各症候比较,P0.05,具有明显差异。组间比较,实验组治疗后与对照组治疗后各症候比较,P0.05,具有明显差异。3.实验组治疗后结肠黏膜有效率93.75%,对照组治疗后结肠黏膜有效率为54.55%,实验组与对照组黏膜有效率比较,P0.05,具有明显差异。4.实验组治疗过程中复发率3.13%,对照组治疗过程中复发率为21.21%,实验组与对照组复发率比较,P0.05,具有明显差异。5.实验组治疗过程中无受试者发生不良反应,对照组治疗过程中不良反应发生率为15.15%,实验组与对照组不良反应发生率比较,P0.05,具有明显差异。结论:1.健脾温肾汤能明显改善缓解期脾溃疡性结肠炎(脾肾阳虚证)患者的腹泻、腹痛、腹胀、里急后重、便血、形寒肢冷、腰膝酸软等症状,能促进肠黏膜愈合,且较美沙拉嗪肠溶片有明显优势。2.健脾温肾汤治疗缓解期溃疡性结肠炎(脾肾阳虚证)患者的复发率较美沙拉嗪肠溶片低,不良反应少,可做为维持治疗缓解期溃疡性结肠炎(脾肾阳虚证)安全有效的药物。
[Abstract]:Objective: to observe the clinical efficacy and safety of Jianpi Wenshen decoction (Jianpi Wenshen decoction) in the treatment of remission ulcerative colitis (spleen and kidney yang deficiency syndrome), and to compare the recurrence rate of Jianpi Wenshen decoction and mesalazine enteric coated tablets in the treatment of remission ulcerative colitis. Methods: from January 2015 to July 2015, 68 subjects who met the inclusion criteria and excluded criteria were randomly divided into experimental group (n = 34) and radiation group (n = 34). The experimental group was treated with Jianpi Wenshen decoction, the control group was treated with mesalazine enteric-coated tablets for 12 weeks. The changes of symptoms and recurrence rate during treatment were recorded in detail. At the end of the course, the subjects came to the hospital to review and collect the collected data, set up the database, and use SPSS18.0 software to make statistics, analysis and record the statistical results. The result is 1: 1. The comprehensive effective rate of experimental group was 93.76%, that of control group was 87.88%, and that of experimental group was significantly higher than that of control group (P 0.05). The effective rate of TCM syndromes was 96.866.86 in the experimental group and 63.64in the control group. There was significant difference between the experimental group before treatment and after treatment (P0.05). The symptoms of the control group were significantly different before and after treatment (P 0.05). Comparison between groups, the experimental group after treatment and control group after the treatment of symptoms, P0.05, with significant difference. The effective rate of colonic mucosa in the experimental group was 93.75 and that in the control group was 54.55.The effective rate of the experimental group was significantly higher than that of the control group (P 0.05). The relapse rate was 3.13 in the experimental group and 21.21 in the control group. The recurrence rate in the experimental group was significantly different from that in the control group (P 0.05). There were no adverse reactions in the experimental group and 15.15 in the control group. There was a significant difference between the experimental group and the control group in the incidence of adverse reactions (P0.05). Conclusion: 1. Jianpi Wenshen decoction can obviously improve the diarrhea, abdominal pain, abdominal distension, blood stool, cold limbs, sore waist and knee in patients with splenic ulcerative colitis (spleen and kidney yang deficiency syndrome) in remission period, and can promote the healing of intestinal mucosa. Compared with mesalazine enteric coated tablets, it has obvious advantage. 2. The relapse rate of Jianpi Wenshen decoction in the treatment of ulcerative colitis (spleen and kidney yang deficiency syndrome) is lower than that of mesalazine enteric coated tablets, and it can be used as a safe and effective drug for the treatment of ulcerative colitis (spleen and kidney yang deficiency syndrome) in remission period.
【学位授予单位】：河南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】